Complications in patients after intravitreal injection of bevacizumab
Complications in patients after intravitreal injection of bevacizumab
复制标题
DOI：
10.1111/j.1600-0420.2007.01067.x
复制
发表时间：
2008-06-01
影响因子：
3.4
通讯作者：
Tano, Yasuo
中科院分区：
文献类型：
--
作者：
Shima, Chiharu;Sakaguchi, Hirokazu;Tano, Yasuo
目的：报告玻璃体内注射贝伐单抗治疗与血管内皮生长因子相关的眼部疾病后的并发症。方法：回顾707例眼内新生血管或黄斑水肿患者(1300次注射)玻璃体腔内注射贝伐单抗后2个月内发生的全身和眼部并发症。结果：707例患者中发生9例眼部并发症(1.27%)和8例全身并发症(1.13%)。眼部并发症包括角膜擦伤2例，晶状体混浊2例，晶状体损伤1例，炎症2例，视网膜色素上皮撕裂1例，急性视力丧失1例。全身并发症包括脑梗塞1例，血压升高2例，面部皮肤红肿1例，瘙痒弥漫性皮疹1例，月经不调3例。结论：玻璃体内注射贝伐单抗可引起全身或眼部并发症。当考虑玻璃体内注射这种药物时，建议谨慎。
Purpose: To report complications in patients after intravitreal injection of bevacizumab to treat ocular diseases associated with vascular endothelial growth factor.Methods: We retrospectively reviewed the systemic and ocular complications that developed within 2 months of each intravitreal injection of bevacizumab in 707 patients (1300 injections) with intraocular neovascularization or macular oedema.Results: Nine ocular (1.27%) and eight systemic (1.13%) complications occurred in 707 patients. The ocular complications included corneal abrasion (n = 2), chemosis (n = 2), lens injury (n = 1), ocular inflammation (n = 2), retinal pigment epithelial tear (n = 1) and acute vision loss (n = 1). The systemic complications included cerebral infarction (n = 1), elevation of systolic blood pressure (n = 2), facial skin redness (n = 1), itchy diffuse rash (n = 1) and menstrual irregularities (n = 3).Conclusion: Intravitreal injection of bevacizumab may cause systemic or ocular complications. Caution is advised when considering intravitreal injection of this drug.